Cytomegalovirus Infections Clinical Trial
Official title:
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes for the Prophylaxis and Treatment of EBV, CMV, and Adenovirus Infection Post Allogeneic Stem Cell Transplant (VIRAGE)
Patient's on this protocol have a type of blood cell cancer, other blood disease or a
genetic disease and have received a stem cell transplant. The donor of the stem cells was
either a brother or sister, another relative, or a closely matched unrelated donor. The
patient is being asked to participate in this study which tests if blood cells from the
donor that have been grown in a special way, can prevent or be an effective treatment for
early infection by three viruses - Epstein Barr virus (EBV), cytomegalovirus (CMV) and
adenovirus.
Adenovirus is a virus that usually causes symptoms of a common cold, but can cause serious
life-threatening infections in patients who have weak immune systems. It can affect the
lungs and cause very serious pneumonia, and can also damage the gut, liver, pancreas and
eyes.CMV can also cause serious infections in patients with weak or suppressed immune
systems. It usually affects the lungs, causing a very serious pneumonia, but it can also
affect the gut, the liver and the eyes. Approximately 2/3 of normal people harbor this virus
in their body. In healthy people CMV rarely causes any problems because the immune system
can keep it under control, but after a transplant, the risk of developing CMV disease is
much higher because the immune system is so weak. EBV is the virus that causes glandular
fever. It is also a life long infection like CMV that is normally controlled by the immune
system. When immunity is weak, the virus can become active and cause fevers, enlarged lymph
nodes and sometimes a type of cancer called lymphoma.
Investigators want to see if a kind of white blood cell called T lymphocytes (T cells)can be
used to prevent and treat adenovirus, CMV and EBV in the early stages of reactivation or
infection. T cells have been grown from the patient's stem cell donor in the laboratory in a
way that will train them to recognize the virus and control it when they are given after a
transplant. This treatment with specially trained T cells (also called CTLs) has had
activity against these viruses in previous studies and in this study investigators want to
see if they still have activity when they are made in a simpler and faster way. These
donor-derived multivirus-specific special cell lines are an investigational product not
approved by the Food and Drug Administration.
The purpose of this study is to evaluate whether donor-derived multivirus-specific special
cell lines are safe and can control three viruses: EBV, CMV and adenovirus.
Blood has been previously taken from the patient and the donor to make the cells.
To make the special cell line, special blood cells called dendritic cells (DCs)were made
first from the donor blood. Then, a specially produced gene called a plasmid that carries
the adenovirus, CMV, and EBV genes was introduced into the dendritic cells. Dendritic cells
with these new genes are then mixed with T cells to stimulate them. This stimulation trains
the donor T cells to kill cells that are infected with CMV, EBV, and adenovirus. Once a
sufficient numbers of T cells were made, they were tested to make sure they killed the
patient's cells infected with these viruses, but not the patient's normal cells, and were
frozen.
If the donor has never been infected with CMV, the CTLs made for the patient may not have
activity against a CMV infection. If these donor CTLs show no activity against CMV
infection, the cells will not be given.
The patient may receive Benadryl (diphenhydramine) and Tylenol (acetaminophen). Then, the
donor's special cells will be thawed and injected into the patient's intravenous line. After
the patient receives the cells, the levels of these three viruses in the patient's blood
will be monitored. Investigators will also take blood to see how long the T cells given to
the patient are lasting in the patient's body.
If the special cell infusion has helped the infection or if the patient has had a treatment
(for example with steroid drugs) that might have destroyed the T cells that were given to
them, then the patient is allowed to receive up to 2 more doses of the cells.
The patient will continue to be followed by his/her transplant doctors after the injection.
The patient will either be seen in the clinic or contacted by a research nurse to follow up
for this study every week for 6 weeks then at 8 weeks, and 3, 6, and 12 months. The patient
may have other visits for standard care.
The patient will also have regular blood tests done to follow counts and the viral
infection. To learn more about the way the T cells are working in the patient's body, up to
an extra 30-40 ml (6-8 teaspoons) of blood will be taken before the infusion and then at 1,
2, 4, 6, and 8 weeks and 3 months. Blood should come from the central intravenous line, and
should not require extra needle sticks. Total time participation for this study will be 1
year.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03950414 -
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
|
Phase 1 | |
Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Recruiting |
NCT02671318 -
Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
|
Phase 4 | |
Completed |
NCT01325636 -
Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus
|
Phase 1/Phase 2 | |
Recruiting |
NCT00228202 -
Genotyping of Cytomegalovirus From Patients in Israel
|
N/A | |
Completed |
NCT00031421 -
Neonatal CMV-Ganciclovir Follow-up Study
|
N/A | |
Completed |
NCT00005496 -
Inflammation, Infection, and Future Cardiovascular Risk
|
N/A | |
Terminated |
NCT03262194 -
Relevance of Gastric Aspirate in HCMV Detection
|
||
Completed |
NCT04478474 -
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
|
||
Recruiting |
NCT05370976 -
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
|
Phase 2 | |
Active, not recruiting |
NCT02943057 -
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
|
Phase 4 | |
Completed |
NCT02538172 -
Cell-mediated Immunity for Prevention of CMV Disease
|
N/A | |
Completed |
NCT02642822 -
The Epidemiologic Study of Human Cytomegalovirus(CMV) in Female Students of Xiamen University
|
N/A | |
Completed |
NCT02134184 -
The Influence of Chronic CMV Infection on Influenza Vaccine Responses
|
Phase 4 | |
Completed |
NCT00673868 -
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
|
Phase 1 | |
Active, not recruiting |
NCT05089630 -
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06058858 -
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
|
||
Active, not recruiting |
NCT04904614 -
Letermovir Use in Heart Transplant Recipients
|
Phase 4 | |
Completed |
NCT01986010 -
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
|
Phase 1 |